aflibercept
Sandoz shares positive results from MYLIGHT phase 3 study
August 16, 2023Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration
Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …
Bayer and Regeneron eye drug gains another indication
March 26, 2015Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept
Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …
New EU indication for Bayer and Regeneron eye drug
February 27, 2015Sales and Marketing Bayer, European Commission, Eylea, aflibercept
Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Bayer eye drug succeeds in long-term study
February 21, 2012Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD
Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition. The Phase III …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
